Please Wait.....
Report
Systemic Sclerosis Market Report and Forecast 2024-2032
Market Report (7 days) I 2024-02-13 I 180 Pages I EMR Inc.
Systemic Sclerosis Market Report and Forecast 2024-2032
Systemic Sclerosis Market Outlook
The systemic sclerosis market size is anticipated to grow at a CAGR of 6.3% during the forecast period of 2024-2032, driven by development of novel therapies targeting the underlying mechanisms of systemic sclerosis across the major markets.
Systemic Sclerosis: Introduction
Systemic sclerosis also known as scleroderma, is a rare chronic autoimmune disease characterized by the hardening and tightening of the skin and connective tissues. It affects not only the skin but also internal organs such as the heart, lungs, kidneys, and gastrointestinal tract, leading to various complications. Symptoms can include skin thickening, joint pain, digestive issues, and Raynaud's phenomenon. The exact cause of Systemic sclerosis is unknown, and treatment focuses on managing symptoms and preventing organ damage.
Key Trends in the Systemic Sclerosis Market
There's a global trend towards the development of novel therapies targeting the underlying mechanisms of systemic sclerosis. This includes research into immunosuppressants, biologics, and targeted therapies that aim to modulate the immune response and fibrotic processes characteristic of Systemic sclerosis. Clinical trials are exploring the efficacy of these new treatment approaches, offering hope for improved patient outcomes.
The market is seeing a shift towards personalized medicine, with treatments being tailored based on individual patient characteristics, disease subtypes, and severity. Biomarker research is gaining traction, aiming to identify patients who are more likely to respond to specific therapies. This approach seeks to optimize treatment effectiveness and reduce adverse effects.
There's an increasing emphasis on multidisciplinary care models to address the complex, multi-organ involvement in systemic sclerosis. Specialized centers that offer comprehensive care involving rheumatologists, dermatologists, pulmonologists, and other specialists are becoming more common. These centers focus on holistic patient management, integrating pharmacological treatments with physical therapy, patient education, and psychological support.
Awareness campaigns and patient advocacy groups are playing a vital role in increasing public and healthcare professional awareness of systemic sclerosis. These efforts are improving early diagnosis and access to care. Support networks provide valuable resources and emotional support for patients and their families, helping to navigate the challenges of living with Systemic sclerosis.
Given the rarity of systemic sclerosis, many treatments fall under orphan drug status, benefiting from regulatory incentives designed to encourage the development of drugs for rare diseases. This support facilitates research and development activities, expedites the approval process, and ultimately brings innovative treatments to the market more quickly.
Systemic Sclerosis Market Segmentation
Market Breakup by Diagnosis
- Skin Biopsy
- Imaging Techniques
- Blood test
- Electrocardiogram
- Pulmonary Function Test
Market Breakup by Type
- Limited Systemic Sclerosis
- Diffuse Systemic Sclerosis
- Sine Systemic Sclerosis
Market Breakup by Drug Class
- Immunosuppressors
- PDE-5 Inhibitors
- Endothelin Receptor Antagonist
- Prostacyclin Analogues
- Others
Market Breakup by End User
- Hospitals
- Clinics
- Research Institutes
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
o Germany
o France
o Italy
o Spain
o United Kingdom
- Japan
Systemic Sclerosis Market Overview
In North America, the systemic sclerosis market is characterized by a strong focus on research and development of new treatments and a comprehensive approach to patient care. The region benefits from advanced healthcare infrastructure and a high level of awareness about autoimmune diseases. There's a significant emphasis on personalized medicine and the use of immunosuppressive drugs, alongside therapies targeting specific symptoms and organ involvement. Patient advocacy groups play a crucial role in supporting research and improving access to care.
Europe's market is driven by well-established healthcare systems and robust support for rare disease research, including systemic sclerosis. Collaborative research efforts across European countries aim to understand the disease better and develop more effective treatments. The European Medicines Agency (EMA) provides regulatory pathways for orphan drugs, facilitating the development of new therapies. Integrated care models, combining pharmacological treatments with physical therapy and psychological support, are essential aspects of managing the condition.
In Japan, the systemic sclerosis market benefits from a strong emphasis on healthcare innovation and a proactive approach to addressing rare diseases. The country has a well-developed healthcare system and policies supporting the development and approval of treatments for conditions like systemic sclerosis. Japan's market is notable for its focus on early diagnosis and the use of cutting-edge technologies and therapies. Research and clinical trials in Japan often explore novel therapeutic approaches, including stem cell therapy and targeted molecular treatments.
Systemic Sclerosis Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players.
- F. Hoffmann La Roche Ltd.
- Johnson & Johnson Services
- United Therapeutics
- Boehringer Ingelheim International GmbH
- GlaxoSmithKline plc
- Pfizer
- Eli Lilly and Company
- Bayer AG
- Mylan N.V.
- Teva Pharmaceutical Industries Ltd.
- Gilead Sciences Inc
- Novartis AG
- Cumberland Pharmaceuticals
- Organon LLC
- Lupin Ltd.
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Systemic Sclerosis Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Systemic Sclerosis Epidemiology Analysis - Seven Major Markets
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Systemic Sclerosis Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Systemic Sclerosis Epidemiology Forecast (2017-2032)
5.3.1 Germany Systemic Sclerosis Epidemiology Forecast (2017-2032)
5.3.2 France Systemic Sclerosis Epidemiology Forecast (2017-2032)
5.3.3 Italy Systemic Sclerosis Epidemiology Forecast (2017-2032)
5.3.4 Spain Systemic Sclerosis Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Systemic Sclerosis Epidemiology Forecast (2017-2032)
5.4 Japan Systemic Sclerosis Epidemiology Forecast (2017-2032)
6 Systemic Sclerosis Market Overview - Seven Major Markets
6.1 Systemic Sclerosis Market Historical Value (2017-2023)
6.2 Systemic Sclerosis Market Forecast Value (2024-2032)
7 Systemic Sclerosis Market Landscape - Seven Major Markets
7.1 Systemic Sclerosis Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Systemic Sclerosis Product Landscape
7.2.1 Analysis by Products
7.2.2 Analysis by Indications
7.2.3 Analysis by Route of Administration
8 Systemic Sclerosis Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Systemic Sclerosis Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter's Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Systemic Sclerosis Market Segmentation - Seven Major Markets
11.1 Systemic Sclerosis Market by Diagnosis
11.1.1 Market Overview
11.1.2 Skin Biopsy
11.1.3 Imaging Techniques
11.1.4 Blood Test
11.1.5 Electrocardiogram
11.1.6 Pulmonary Function Test
11.2 Systemic Sclerosis Market by Type
11.2.1 Market Overview
11.2.2 Limited Systemic Sclerosis
11.2.3 Diffuse Systemic Sclerosis
11.2.4 Sine Systemic Sclerosis
11.3 Systemic Sclerosis Market by Drug Class
11.3.1 Market Overview
11.3.2 Immunosuppressors
11.3.3 PDE-5 Inhibitors
11.3.4 Endothelin Receptor Antagonist
11.3.5 Prostacyclin Analogues
11.3.6 Biologics
11.3.7 Others
11.4 Systemic Sclerosis Market by End User
11.4.1 Market Overview
11.4.2 Hospitals
11.4.3 Clinics
11.4.4 Research Institutes
11.4.5 Others
11.5 Systemic Sclerosis Market by Region
11.5.1 Market Overview
11.5.2 United States
11.5.3 EU-4 and the United Kingdom
11.5.3.1 Germany
11.5.3.2 France
11.5.3.3 Italy
11.5.3.4 Spain
11.5.3.5 United Kingdom
11.5.4 Japan
12 United States Systemic Sclerosis Market
12.1 Systemic Sclerosis Market Historical Value (2017-2023)
12.2 Systemic Sclerosis Market Forecast Value (2024-2032)
12.3 Systemic Sclerosis Market by Diagnosis
12.4 Systemic Sclerosis Market by Drug Class
13 EU-4 and United Kingdom Systemic Sclerosis Market
13.1 Systemic Sclerosis Market Historical Value (2017-2023)
13.2 Systemic Sclerosis Market Forecast Value (2024-2032)
13.3 Germany Systemic Sclerosis Market Overview
13.3.1 Systemic Sclerosis Market by Diagnosis
13.3.2 Systemic Sclerosis Market by Drug Class
13.4 France Systemic Sclerosis Market Overview
13.4.1 Systemic Sclerosis Market by Diagnosis
13.4.2 Systemic Sclerosis Market by Drug Class
13.5 Italy Systemic Sclerosis Market Overview
13.5.1 Systemic Sclerosis Market by Diagnosis
13.5.2 Systemic Sclerosis Market by Drug Class
13.6 Spain Systemic Sclerosis Market Overview
13.6.1 Systemic Sclerosis Market by Diagnosis
13.6.2 Systemic Sclerosis Market by Drug Class
13.7 United Kingdom Systemic Sclerosis Market Overview
13.7.1 Systemic Sclerosis Market by Diagnosis
13.7.2 Systemic Sclerosis Market by Drug Class
14 Japan Systemic Sclerosis Market
14.1 Systemic Sclerosis Market Historical Value (2017-2023)
14.2 Systemic Sclerosis Market Forecast Value (2024-2032)
14.2.1 Systemic Sclerosis Market by Diagnosis
14.2.2 Systemic Sclerosis Market by Drug Class
15 Patent Analysis
15.1 Analysis by Type of Patent
15.2 Analysis by Publication year
15.3 Analysis by Issuing Authority
15.4 Analysis by Patent Age
15.5 Analysis by CPC Analysis
15.6 Analysis by Patent Valuation
15.7 Analysis by Key Players
16 Grants Analysis
16.1 Analysis by year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Application
16.5 Analysis by Funding Institute
16.6 Analysis by NIH Departments
16.7 Analysis by Recipient Organization
17 Clinical Trials Analysis
17.1 Analysis by Trial Registration Year
17.2 Analysis by Trial Status
17.3 Analysis by Trial Phase
17.4 Analysis by Therapeutic Area
17.5 Analysis by Geography
18 Funding Analysis
18.1 Analysis by Funding Instances
18.2 Analysis by Type of Funding
18.3 Analysis by Funding Amount
18.4 Analysis by Leading Players
18.5 Analysis by Leading Investors
18.6 Analysis by Geography
19 Partnership and Collaborations Analysis
19.1 Analysis by Partnership Instances
19.2 Analysis by Type of Partnership
19.3 Analysis by Leading Players
19.4 Analysis by Geography
20 Supplier Landscape
20.1 F. Hoffmann La Roche Ltd.
20.1.1 Financial Analysis
20.1.2 Product Portfolio
20.1.3 Demographic Reach and Achievements
20.1.4 Mergers and Acquisition
20.1.5 Certifications
20.2 Johnson & Johnson Services
20.2.1 Financial Analysis
20.2.2 Product Portfolio
20.2.3 Demographic Reach and Achievements
20.2.4 Mergers and Acquisition
20.2.5 Certifications
20.3 United Therapeutics
20.3.1 Financial Analysis
20.3.2 Product Portfolio
20.3.3 Demographic Reach and Achievements
20.3.4 Mergers and Acquisition
20.3.5 Certifications
20.4 Boehringer Ingelheim International GmbH
20.4.1 Financial Analysis
20.4.2 Product Portfolio
20.4.3 Demographic Reach and Achievements
20.4.4 Mergers and Acquisition
20.4.5 Certifications
20.5 GlaxoSmithKline plc
20.5.1 Financial Analysis
20.5.2 Product Portfolio
20.5.3 Demographic Reach and Achievements
20.5.4 Mergers and Acquisition
20.5.5 Certifications
20.6 Pfizer
20.6.1 Financial Analysis
20.6.2 Product Portfolio
20.6.3 Demographic Reach and Achievements
20.6.4 Mergers and Acquisition
20.6.5 Certifications
20.7 Eli Lilly and Company
20.7.1 Financial Analysis
20.7.2 Product Portfolio
20.7.3 Demographic Reach and Achievements
20.7.4 Mergers and Acquisition
20.7.5 Certifications
20.8 Bayer AG
20.8.1 Financial Analysis
20.8.2 Product Portfolio
20.8.3 Demographic Reach and Achievements
20.8.4 Mergers and Acquisition
20.8.5 Certifications
20.9 Mylan N.V.
20.9.1 Financial Analysis
20.9.2 Product Portfolio
20.9.3 Demographic Reach and Achievements
20.9.4 Mergers and Acquisition
20.9.5 Certifications
20.10 Teva Pharmaceutical Industries Ltd.
20.10.1 Financial Analysis
20.10.2 Product Portfolio
20.10.3 Demographic Reach and Achievements
20.10.4 Mergers and Acquisition
20.10.5 Certifications
20.11 Gilead Sciences Inc.
20.11.1 Financial Analysis
20.11.2 Product Portfolio
20.11.3 Demographic Reach and Achievements
20.11.4 Mergers and Acquisition
20.11.5 Certifications
20.12 Novartis AG
20.12.1 Financial Analysis
20.12.2 Product Portfolio
20.12.3 Demographic Reach and Achievements
20.12.4 Mergers and Acquisition
20.12.5 Certifications
20.13 Cumberland Pharmaceuticals
20.13.1 Financial Analysis
20.13.2 Product Portfolio
20.13.3 Demographic Reach and Achievements
20.13.4 Mergers and Acquisition
20.13.5 Certifications
20.14 Organon LLC
20.14.1 Financial Analysis
20.14.2 Product Portfolio
20.14.3 Demographic Reach and Achievements
20.14.4 Mergers and Acquisition
20.14.5 Certifications
20.15 Lupin Ltd
20.15.1 Financial Analysis
20.15.2 Product Portfolio
20.15.3 Demographic Reach and Achievements
20.15.4 Mergers and Acquisition
20.15.5 Certifications
21 Systemic Sclerosis Market - Distribution Model (Additional Insight)
21.1 Overview
21.2 Potential Distributors
21.3 Key Parameters for Distribution Partner Assessment
22 Key Opinion Leaders (KOL) Insights (Additional Insight)
23 Company Competitiveness Analysis (Additional Insight)
23.1 Very Small Companies
23.2 Small Companies
23.3 Mid-Sized Companies
23.4 Large Companies
23.5 Very Large Companies
24 Payment Methods (Additional Insight)
24.1 Government Funded
24.2 Private Insurance
24.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security